Fecal microbiota transplantation for Clostridium difficile infection: Back to the future

Expert Opinion on Biological Therapy

Volumn 15, Issue 7, 2015, Pages 1001-1014

  Borgia, Guglielmo ^a   Maraolo, Alberto Enrico ^a   Foggia, Maria ^a   Buonomo, Antonio Riccardo ^a   Gentile, Ivan ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antibiotics; Clostridium difficile infection; Diarrhea; Dysbiosis; Feces; Gut; Microbiota; Recurrence

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; FECES MICROFLORA TRANSPLANTATION; HUMAN; INTESTINE FLORA; NONHUMAN; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW; THERAPY; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM INFECTIONS; EVIDENCE BASED PRACTICE; FECAL MICROBIOTA TRANSPLANTATION; FECES; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOPHYSIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; RECURRENT DISEASE;

CLOSTRIDIUM DIFFICILE;

CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; EVIDENCE-BASED PRACTICE; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; RECURRENCE;

EID: 84931027078     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1045872     Document Type: Review

References (124)

1. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver 2014;8:1-6
2. Hall I, O'Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, bacillus difficilis. Am J Dis Child 1935;49:309-402
3. Bassetti M, Villa G, Pecori D, et al. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther 2012;10:1405-23
4. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978;298:531-4
5. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-36
6. Yakob L, Riley TV, Paterson DL, et al. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect Dis 2013;13:1471-2334
7. Bobulsky GS, Al-Nassir WN, Riggs MM, et al. Clostridium difficile skin contamination in patients with C. difficile-associated disease. Clin Infect Dis 2008;46:447-50
8. Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013;369:1195-205
9. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. Cmaj 2004;171:51-8
10. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006;73:187-97
11. Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014;14:1208-19
12. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-40
13. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198-208
14. Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011;32:387-90
15. Lucado J, Gould C, Elixhauser A. Clostridium difficile Infections (CDI) in Hospital Stays, 2009: Statistical Brief #124. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Health Care Policy and Research (US): 2006-2012
16. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist 2014;7:63-72
17. He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013;45:109-13
18. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012;55:216-23
19. Collins DA, Hawkey PM, Riley TV. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control 2013;2:2047-994
20. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478-98
21. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012;6:5-12
22. Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile infections. Clin Microbiol Infect 2012;18(Suppl 6):2-4
23. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;2:1-26
24. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012;6:21-7
25. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50
26. Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin North Am 2012;41:781-803
27. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8
28. Singh R, Nieuwdorp M, ten Berge IJ, et al. The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection. Clin Microbiol Infect 2014;20:1119-25
29. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1, 700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012;107:1755
30. Ley RE, Lozupone CA, Hamady M, et al. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol 2008;6:776-88
31. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004;38:475-83
32. Lewin RA. Merde: excursions in scientific, cultural and socio-historical coprology. Random House; New York: 1999
33. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854-9
34. Schwan A, Sjolin S, Trottestam U, et al. Relapsing Clostridium difficileenterocolitis cured by rectal infusion of homologous faeces. Lancet 1983;2(8354):845
35. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013;29:79-84
36. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580-5
37. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000;95:3283-5
38. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010;8:471-3
39. Fujimura KE, Slusher NA, Cabana MD, et al. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther 2010;8:435-54
40. Aziz Q, Dore J, Emmanuel A, et al. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil 2013;25:4-15
41. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904
42. Dominguez-Bello MG, Blaser MJ, Ley RE, et al. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 2011;140:1713-19
43. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635-8
44. Rajilic-Stojanovic M, Heilig HG, Tims S, et al. Long-term monitoring of the human intestinal microbiota composition. Environ Microbiol 2012;15:1462-2920
45. Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human gut microbiota. Science 2013;341:1237439
46. Bruggemann H, Gottschalk G. Comparative genomics of clostridia: link between the ecological niche and cell surface properties. Ann NY AcadSci 2008;1125:73-81
47. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 2012;20:313-19
48. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol 2013;6:53-68
49. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. Altern Med Rev 2004;9:180-97
50. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001;1:101-14
51. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. Jama 2005;294:2989-95
52. Bibbo S, Lopetuso LR, Ianiro G, et al. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J Immunol Res 2014;2014:462740
53. Freter R. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora. J Infect Dis 1955;97:57-65
54. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9
55. Bartlett JG. Clostridium difficile: progress and challenges. Ann NY Acad Sci 2010;1213:62-9
56. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53:42-8
57. Borody TJ, Brandt LJ, Paramsothy S, et al. Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection: Expert Rev Anti Infect Ther. 2013;11(5):447-9
58. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014;59:345-54
59. Wilcox MH. Editorial Commentary: the trials and tribulations of treating Clostridium difficile infection-one step backward, one step forward, but still progress. Clin Infect Dis 2014;59:355-7
60. Agito MD, Atreja A, Rizk MK. Fecal microbiota transplantation for recurrent C. difficile infection: ready for prime time? Cleve Clin J Med 2013;80:101-8
61. Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010;44:354-60
62. Fuentes S, van Nood E, Tims S, et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. Isme J 2014;8:1621-33
63. van Nood E, Dijkgraaf MG, Keller JJ. Duodenal infusion of feces for recurrent Clostridium difficile. N Engl J Med 2013;368:2145
64. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014;146:1573-82
65. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014;146:1547-53
66. Freter R, Brickner H, Botney M, et al. Mechanisms that control bacterial populations in continuous-flow culture models of mouse large intestinal flora. Infect Immun 1983;39:676-85
67. Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002;186:1781-9
68. Vincent C, Stephens DA, Loo VG, et al. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome 2013;1:2049-618
69. Rea MC, Dobson A, O'Sullivan O, et al. Effect of broad-and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 2011;108(Suppl 1):4639-44
70. Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014;306:310-19
71. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008;190:2505-12
72. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008;65:2461-83
73. Sorg JA, Sonenshein AL. Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol 2009;191:1115-17
74. Giel JL, Sorg JA, Sonenshein AL, et al. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 2010;5:e8740
75. Peniche AG, Savidge TC, Dann SM. Recent insights into Clostridium difficile pathogenesis. Curr Opin Infect Dis 2013;26:447-53
76. Macpherson AJ, McCoy KD. Stratification and compartmentalisation of immunoglobulin responses to commensal intestinal microbes. Semin Immunol 2013;25:358-63
77. Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011;60:1070-9
78. Ryan A, Lynch M, Smith SM, et al. A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog 2011;7:e1002076
79. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-41
80. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012;8:e1002995
81. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013;78:240-9
82. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044-9
83. Lagier JC. Faecal microbiota transplantation: from practice to legislation before considering industrialization. Clin Microbiol Infect 2014;20:1112-18
84. Kapel N, Thomas M, Corcos O, et al. Practical implementation of faecal transplantation. Clin Microbiol Infect 2014;20:1098-105
85. Owens C, Broussard E, Surawicz C. Fecal microbiota transplantation and donor standardization. Trends Microbiol 2013;21:443-5
86. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53:994-1002
87. Kassam Z, Lee CH, Hunt RH. Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med 2014;34:787-98
88. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014;58:1515-22
89. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. Jama 2014;312:1772-8
90. Dinleyici EC, Eren M, Ozen M, et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012;12:395-410
91. Zipursky JS, Sidorsky TI, Freedman CA, et al. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012;55:1652-8
92. Zipursky JS, Sidorsky TI, Freedman CA, et al. Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. Can J Gastroenterol Hepatol 2014;28:319-24
93. Duke PS, Fardy J. Recurrent Clostridium difficile infection treated with home fecal transplantation: a case report. J Med Case Rep 2014;8:1752-947
94. Wilson DE, Chosewood LC. Biosafety in Microbiological and Biomedical Laboratories, (BMBL), Centers for Disease Control and Prevention/National Institute of Health. 5th edition. U.S. Government Printing Office; Washington, DC: 2009
95. Zanella Terrier MC, Simonet ML, et al. Recurrent Clostridium difficile infections: the importance of the intestinal microbiota. World J Gastroenterol 2014;20:7416-23
96. Vyas D, L'Esperance H E, Vyas A. Stool therapy may become a preferred treatment of recurrent Clostridium difficile? World J Gastroenterol 2013;19:4635-7
97. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014;48:693-702
98. Konijeti GG, Sauk J, Shrime MG, et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;58:1507-14
99. Varier RU, Biltaji E, Smith KJ, et al. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect 2014;20:1343-51
100. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014;109:1065-71
101. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013;108:177-85
102. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013;11:1036-8
103. Koenigsknecht MJ, Young VB. Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs. Curr Opin Gastroenterol 2013;29:628-32
104. Austin M, Mellow M, Tierney WM. Fecal microbiota transplantation in the treatment of Clostridium difficile infections. Am J Med 2014;127:479-83
105. Petrof EO, Claud EC, Gloor GB, et al. Microbial ecosystems therapeutics: a new paradigm in medicine? Benef Microbes 2013;4:53-65
106. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficilediarrhoea in six patients. Lancet 1989;1:1156-60
107. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013;1:2049-618
108. Adamu BO, Lawley TD. Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Curr Opin Microbiol 2013;16:596-601
109. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. Jama 2015;313:398-408
110. Borody TJ, Peattie D, Kapur A. Could fecal microbiota transplantation cure all Clostridium difficile infections? Future Microbiol 2014;9:1-3
111. Khoruts A. Faecal microbiota transplantation in 2013: developing human gut microbiota as a class of therapeutics. Nat Rev Gastroenterol Hepatol 2014;11:79-80
112. Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect 2012;6:28-35
113. Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014;69:2892-900
114. Bartsch SM, Umscheid CA, Fishman N, et al. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013;57:555-61
115. Vassallo A, Tran MC, Goldstein EJ. Clostridium difficile: improving the prevention paradigm in healthcare settings. Expert Rev Anti Infect Ther 2014;12:1087-102
116. De Palma M, Grillo M, Borgia G, et al. Antibiotic prophylaxis and risk of infections in thyroid surgery: results from a national study (UEC-Italian Endocrine Surgery Units Association). Updates Surg 2013;65:213-16
117. Gentile I, Rosato L, Avenia N, et al. Do Italian surgeons use antibiotic prophylaxis in thyroid surgery? Results from a national study (UEC-Italian Endocrine Surgery Units Association). Ann Ital Chir 2014;85:33-7
118. Abou Chakra CN, Pepin J, Sirard S, et al. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014;9:e98400
119. Garborg K, Waagsbo B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010;42:857-61
120. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012;142:490-6
121. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:1079-87
122. Jorup-Ronstrom C, Hakanson A, Sandell S, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012;47:548-52
123. Rubin TA, Gessert CE, Aas J, et al. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe 2013;19:22-6
124. Terwee CB, Mokkink LB, Knol DL, et al. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 2012;21:651-7